文献リスト

1) Golino P, Ragni M, Cirillo P, et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med. 1996; 2: 35-40

2) Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003; 101: 3765-77

3) Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med. 1995; 46: 103-12

4) Collins PW, Noble KE, Reittie JR, et al. Induction of tissue factor expression in human monocyte/endothelium cocultures. Br J Haematol. 1995; 91: 963-70

5) Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A. 1994; 91: 8767-71

6) Cirillo P, Cali G, Golino P, et al. Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation. 2004; 109: 2911-6

7) Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med. 2004; 10: 171-8

8) Chou J, Mackman N, Merrill-Skoloff G, et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood. 2004; 104: 3190-7

9) Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003; 9: 458-62

10) Del Conde I, Shrimpton CN, Thiagarajan P, et al. Tissue factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005; 106: 1604-11

11) Koyama T, Nishida K, Ohdama S, et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol. 1994; 87: 343-7

12) Soejima H, Ogawa H, Yasue H, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation. 1999; 99: 2908-13

13) Diamant M, Nieuwland R, Pablo RF, et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation. 2002; 106: 2442-7

14) 岡本貴行, 鈴木宏治. 組織因子をめぐる最近の話題. In: 高久史麿, 他編. Annual Review血液. 東京: 中外医学社; 2006. p. 248-58

15) Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005; 3: 1800-14

16) Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000; 407: 258-64

17) Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev. 2001; 53: 245-82

18) O'Brien PJ, Molino M, Kahn M, et al. Protease activated receptors: theme and variations. Oncogene. 2001; 20: 1570-81

19) Landis RC. Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am. 2007; 21: 103-13

20) White MC, McHowat J. Protease activation of calcium-independent phospholipase A(2) leads to neutrophil recruitment to coronary artery endothelial cells. Thromb Res. 2007; 120: 597-605

21) Day JR, Landis RC, Taylor KM. Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction. Semin Cardiothorac Vasc Anesth. 2006; 10: 132-42

22) Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation. 2006; 114: 1070-7

23) Lidington EA, Steinberg R, Kinderlerer AR, et al. A role for proteinase-activated receptor 2 and PKC-epsilon in thrombin-mediated induction of decay-accelerating factor on human endothelial cells. Am J Physiol Cell Physiol. 2005; 289: C1437-47

24) Boire A, Covic L, Agarwal A, et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005; 120: 303-13

25) Archiniegas E, Neves CY, Candelle D, et al. Thrombin and its protease-activated receptor-1 (PAR1) participate in the endothelial-mesenchymal transdifferentiation process. DNA Cell Biol. 2004; 23: 815-25

26) Traynelis SF, Trejo J. Protease-activated receptor signaling: new roles and regulatory mechanisms. Curr Opin Hematol. 2007; 14: 230-5

27) Lisman T, Weeterings C, de Groot PG. Platelet aggregation: involvement of thrombin and fibrin(ogen). Front Biosci. 2005; 10: 2504-17

28) Keuren JF, Wielders SJ, Ulrichts H, et al. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler Thromb Vasc Biol. 2005; 25: 1499-505

29) Leger AJ, Jacques SL, Badar J, et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation. 2006; 113: 1244-54

30) Wu CC, Teng CM. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol. 2006; 546: 142-7

31) Holinstat M, Voss B, Bilodeau ML, et al. Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent pathway. Mol Pharmacol. 2007; 71: 686-94

32) Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation. 2006; 114: 1070-7

33) Wielders SJ, Bennaghmouch A, Reutelingsperger CP, et al. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists. J Thromb Haemost. 2007; 5: 571-6

34) Voss B, McLaughlin JN, Holinstat M, et al. PAR1, but not PAR4, activates human platelets through a Gi/o/phosphoinositide-3 kinase signaling axis. Mol Pharmacol. 2007; 71: 1399-406

35) Mazharian A, Roger S, Berrou E, et al. Protease-activating receptor-4 induces full platelet spreading on a fibrinogen matrix: involvement of ERK2 and p38 and Ca2＋ mobilization. J Biol Chem. 2007; 282: 5478-87

36) Erhardt JA, Toomey JR, Douglas SA, et al. P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation. J Thromb Haemost. 2006; 4: 882-90

37) Serebruany VL, Miller M, Pokov AN, et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol. 2006; 97: 1332-6

38) Camerer E, Cormelissen I, Kataoka H, et al. Roles of protease-activated receptors in a mouse model of endotoxiemia. Blood. 2006; 107: 3912-21

39) Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002; 296: 1880-2

40) Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007; 109: 3161-72

41) Feistritzer C, Schuepbauch RA, Mosier LO, et al. Protective signaling by activated protein C is mechanically linked to protein C activation on endothelial cells. Blood. 2005; 105: 3178-84

42) Brueckmann M, Nahrup SA, Lang S, et al. Recombinant human activated protein C upregulates the release of soluble fractalkine from human endothelial cells. Br J Haematol. 2006; 133: 550-7

43) Zioncheck TF, Roy S, Vehar GA. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism. J Biol Chem. 1992; 267: 3561-4

44) Rottingen JA, Enden T, Camerer E, et al. Binding of human factor VIIa to tissue factor induces cytosolic Ca2＋ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. J Biol Chem. 1995; 270: 4650-60

45) Poulsen LK, Jacobsen N, Sorensen BB, et al. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem. 1998; 273: 6228-32

46) Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res. 1996; 81: 1-41

47) Camerer E, Rottingen JA, Gjernes E, et al. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem. 1999; 274: 32225-33

48) Versteeg HH, Hoedemaeker I, Diks SH, et al. Factor VIIa/tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. J Biol Chem. 2000; 275: 28750-6

49) Versteeg HH, Bresser HL, Spek CA, et al. Regulation of the p21Ras-MAP kinase pathway by factor VIIa. J Thromb Haemost. 2003; 1: 1012-8

50) Ollivier V, Bentolila S, Chabbat J, et al. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood. 1998; 91: 2698-703

51) Taniguchi T, Kakkar AK, Tuddenham EG, et al. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res. 1998; 58: 4461-7

52) Wang X, Gjernes E, Prydz H. Factor VIIa induces tissue factor-dependent up-regulation of interleukin-8 in a human keratinocyte line. J Biol Chem. 2002; 277: 23620-6

53) Pendurthi UR, Allen KE, Ezban M, et al. Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa X tissue factor-induced signal transduction. J Biol Chem. 2000; 275: 14632-41

54) Camerer E, Gjernes E, Wiiger M, et al. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem. 2000; 275: 6580-5

55) Versteeg HH, Sorensen BB, Slofstra SH, et al. VIIa/tissue factor interaction results in a tissue factor cytoplasmic domain-independent activation of protein synthesis, p70, and p90 S6 kinase phosphorylation. J Biol Chem. 2002; 277: 27065-72

56) Versteeg HH, Spek CA, Slofstra SH, et al. FVIIa: TF induces cell survival via G12/G13-dependent Jak/STAT activation and BclXL production. Circ Res. 2004; 94: 1032-40

57) Camerer E, Rottingen JA, Iversen JG, et al. Coagulation factors VII and X induce Ca2＋ oscillations in Madin-Darby canine kidney cells only when proteolytically active. J Biol Chem. 1996; 271: 29034-42

58) Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A. 2000; 97: 5255-60

59) Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci U S A 2001; 98: 7742-7

60) Hjortoe GM, Petersen LC, Albrektsen T, et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004; 103: 3029-37

61) Griffin CT, Srinivasan Y, Zheng YW. et al. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science. 2001; 293: 1666-70

62) Marutsuka K, Hatakeyama K, Sato Y, et al. Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Res. 2002; 107: 271-6

63) Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost. 2003; 1: 1495-503

64) Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994; 94: 1320-7

65) Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem. 2000; 275: 1521-4

66) Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004; 10: 502-9

67) Nguyen QD, De Wever O, Bruyneel E, et al. Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. Oncogene. 2005; 24: 8240-51

68) Siegbahn A, Johnell M, Sorensen BB, et al. Regulation of chemotaxis by the cytoplasmic domain of tissue factor. Thromb Haemost. 2005; 93: 27-34

69) Dorfleutner A, Hintermann E, Tarui T, et al. Cross-talk of integrin alpha 3 beta1 and tissue factor in cell migration. Mol Biol Cell. 2004; 15: 4416-25

70) Lau LF, Lam SC. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res. 1999; 248: 44-57

71) Leu SJ, Lam SC, Lau LF. Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alpha v beta3 and alpha6 beta1 in human umbilical vein endothelial cells. J Biol Chem. 2002; 277: 46248-55

72) Arora P, Ricks TK, Trejo J. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci. 2007; 120(Pt 6): 921-8

73) Boire A, Covic L, Agarwal A, et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005; 120: 303-13

74) Rong Y, Post DE, Pieper RO, et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005; 65: 1406-13

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp